Key Points
- BeOne SVP Chan Henry Lee sold 1,660 shares on Feb 4 for $580,203.20, and those trades are part of multiple insider sales from Nov–Feb totaling about $1.26 million.
- ONC opened at $353.92 with a market cap of $38.81 billion and a 52‑week range of $196.45–$385.22, while analysts hold a consensus "Moderate Buy" with a $379.07 target price.
- Institutional investors own roughly 48.55% of the stock, and the company shows solid liquidity (quick ratio 2.17, current ratio 2.39) with very low debt (debt‑to‑equity 0.03).
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 1,660 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $331.76, for a total transaction of $220,288.64.
- On Thursday, December 11th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $325.00, for a total transaction of $107,900.00.
- On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The stock was sold at an average price of $349.17, for a total transaction of $347,773.32.
BeOne Medicines Stock Performance
Shares of ONC stock opened at $353.92 on Friday. The company has a market cap of $38.81 billion, a P/E ratio of 693.96 and a beta of 0.52. The business has a 50 day moving average of $327.94 and a two-hundred day moving average of $324.93. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $196.45 and a 52 week high of $385.22. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03.
Hedge Funds Weigh In On BeOne Medicines
Large investors have recently bought and sold shares of the stock. Anchor Investment Management LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of BeOne Medicines during the second quarter valued at approximately $28,000. Leonteq Securities AG bought a new stake in BeOne Medicines during the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines in the second quarter worth approximately $35,000. Finally, CWM LLC boosted its stake in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.
Analysts Set New Price Targets
ONC has been the topic of several analyst reports. Jefferies Financial Group reaffirmed a "buy" rating and issued a $420.00 target price on shares of BeOne Medicines in a research report on Monday, November 17th. Zacks Research lowered shares of BeOne Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 28th. Barclays lifted their price objective on shares of BeOne Medicines from $385.00 to $394.00 and gave the company an "overweight" rating in a research report on Wednesday. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a research report on Monday, November 24th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating on shares of BeOne Medicines in a report on Wednesday, December 17th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $379.07.
Check Out Our Latest Report on BeOne Medicines
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
